Rosuvastatin + Atorvastatin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metabolic Syndrome X
Conditions
Metabolic Syndrome X
Trial Timeline
Sep 1, 2006 → Jun 1, 2008
NCT ID
NCT00395486About Rosuvastatin + Atorvastatin
Rosuvastatin + Atorvastatin is a approved stage product being developed by AstraZeneca for Metabolic Syndrome X. The current trial status is completed. This product is registered under clinical trial identifier NCT00395486. Target conditions include Metabolic Syndrome X.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00683618 | Phase 3 | Completed |
| NCT00620542 | Phase 3 | Completed |
| NCT00427960 | Approved | Terminated |
| NCT00395486 | Approved | Completed |
| NCT00296400 | Phase 2 | Completed |
| NCT00296387 | Phase 3 | Completed |
| NCT00329173 | Phase 3 | Completed |
| NCT00239330 | Phase 3 | Completed |
| NCT00653965 | Phase 3 | Completed |
| NCT00653588 | Phase 3 | Completed |
| NCT00654225 | Phase 3 | Completed |
| NCT00654485 | Phase 3 | Completed |
| NCT00653744 | Phase 3 | Completed |
Competing Products
20 competing products in Metabolic Syndrome X